Cresilon Showcases TRAUMAGEL at Vizient Innovative Technology Exchange

Monday, 16 September 2024, 05:29

TRAUMAGEL, a cutting-edge hemostatic technology, is set to be showcased by Cresilon at the Vizient Innovative Technology Exchange. This unique product offers novel approaches to bleeding control in medical emergencies. By presenting TRAUMAGEL, Cresilon aims to highlight its commitment to advancing hemostatic medical device technology.
LivaRava_Medicine_Default.png
Cresilon Showcases TRAUMAGEL at Vizient Innovative Technology Exchange

Overview of TRAUMAGEL

TRAUMAGEL is a revolutionary hemostatic medical product by Cresilon, designed to control bleeding rapidly in trauma situations. Utilizing a unique formulation, it works effectively in a variety of clinical settings.

Benefits of TRAUMAGEL

  • Rapid hemostatic action
  • Easy application and usability
  • Versatility across various medical fields

Significance in Emergency Care

By exhibiting TRAUMAGEL at the Vizient Innovative Technology Exchange, Cresilon emphasizes the pivotal role that innovative hemostatic technologies play in improving patient outcomes during emergencies. This exhibition serves as a platform to engage with healthcare professionals about the advances in hemostatic products.


This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.


Related posts


Newsletter

Subscribe to our newsletter for the most accurate and current medical news. Stay updated and deepen your understanding of medical advancements effortlessly.

Subscribe